This report evaluates the use of whole exome sequencing (WES) or whole genome sequencing (WGS) to inform clinical action and improve patient outcomes in children aged ≤ 18 years with undefined neurological phenotypes but no definitive diagnosis following standard diagnostic tests.
Precision Medicine
The explosion of genetic and molecular medicine has produced mountains of options and evidence. Conversely, there is often an alarming lack of evidence. This is where we come in.We help you manage the flood of tests and drugs that emerge in this category daily. Accessed through the Hayes Knowledge Center, our comprehensive Precision Medicine solution focuses on thousands of genetic, genomic, and molecular diagnostic tests and precision medicine therapies addressing the questions our clients most frequently ask:
- Will testing change patient management for this indication?
- If so, what tests and/or therapies should I use?
- Should we cover testing and/or therapies?
- Can we manage these services internally?
- Precision Therapy Assessment
- Clinical Utility Evaluation
- Laboratory Test Insights
- Molecular Test Assessment
- Germline Rapid Reports
- Precision Medicine Research Briefs
Cell-Free DNA (cfDNA) [Formerly NIPS, NIPT] Screening for Fetal Sex Chromosome Aneuploidy
This report evaluates the clinical utility of cell-free DNA (cfDNA) (formerly NIPS, NIPT) screening for fetal sex chromosome aneuploidy (SCA) in women with singleton or twin pregnancies.
GeneSight Psychotropic (Assurex Health Inc./Myriad Neuroscience)
This report evaluates the analytical validity, clinical validity, and clinical utility of the GeneSight Psychotropic (Myriad Neuroscience) test.
Oncotype DX AR-V7 Nucleus Detect (Epic Sciences)
This report evaluates the analytical validity, clinical validity, and clinical utility of the Oncotype DX AR-V7 Nucleus Detect test.
Cell-Free DNA (cfDNA) [Formerly NIPS, NIPT] Screening for Fetal Trisomy 21, 18, and 13 in Women with Twin Pregnancies
This report evaluates the clinical utility of cell-free DNA (cfDNA) (formerly NIPS, NIPT) screening for fetal trisomy 21, 18, and 13 in women with twin pregnancies.
Screening All Women with New Diagnoses of Breast Cancer for Hereditary Cancer Risk Variants
This report evaluates the clinical utility of genetic testing to detect hereditary cancer 1) high risk and 2) moderate risk gene variants in women with new diagnoses of breast cancer (BC), who are not preselected for other risk factors, to improve disease management.
AlloSure Kidney (CareDx Inc.)
This report evaluates the AlloSure Kidney test for acute and chronic kidney transplant rejection (antibody-mediated and/or T-cell mediated) in patients for either surveillance or for-cause evaluation.
Nodify XL2 (Biodesix Inc.)
This report evaluates the analytical validity, clinical validity, and clinical utility of the Nodify XL2 test.
Nodify CDT (Biodesix Inc.)
This report evaluates the analytical validity, clinical validity, and clinical utility of the Nodify CDT test.